🇺🇸 DESOXYRIBONUCLEASE in United States

10 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Acute Promyelocytic Leukaemia — 1 report (10%)
  2. Confusional State — 1 report (10%)
  3. Drug Interaction — 1 report (10%)
  4. Dyspnoea — 1 report (10%)
  5. Hepatic Steatosis — 1 report (10%)
  6. Hyperbilirubinaemia — 1 report (10%)
  7. Hypertransaminasaemia — 1 report (10%)
  8. Leukaemia Recurrent — 1 report (10%)
  9. Papilloedema — 1 report (10%)
  10. Recurrent Cancer — 1 report (10%)

Source database →

DESOXYRIBONUCLEASE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is DESOXYRIBONUCLEASE approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for DESOXYRIBONUCLEASE in United States?

Marketing authorisation holder not available in our data.